Abstract
Background: Chronic kidney diseases become a public health concern as the rate of this diseases is increasing. Thus, the aim of the study was to evaluate the changes in key biomarkers in Bangladeshi CKD stages IV and V patients by using Renadyl capsule.
 Study Design: Open label randomized placebo controlled clinical trial.
 Methods: Data were collected from patients with CKD stage IV and V in 2017, in an out-patient setting in Kidney Foundation Hospital and Research Institute, Bangladesh. Patient’s information, medical history and clinical data were also collected. Health condition of the patients was collected by using SF-36 QOL questionnaire. Data were analyzed using SPSS software version 23.0.
 Results: Administration of Renadyl capsule improved the clinical and biochemical data of the patients. Renadyl administration improved the filtration rate, kidney size, creatinine level, heart rate and liver function. Patient’s physical and mental health was also improved.
 Conclusion: Renadyl administration appeared to be safe among chronic kidney patients with improved kidney function. However, more clinical trials are suggested to determine the efficacy and effects of Renadyl.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Advances in Medical and Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
